Summary The radiolabelled opioid receptor binding affinities of morphine and its active metabolite morphine 6-glucuronide at the total mu, mu 1, mu 2 and delta receptors were determined. Morphine 6-glucuronide was found to have a 4-fold lower affinity for the mu 2 receptor (IC50 17 nm and 82 nm for morphine and morphine 6-glucuronide respectively, P = 0.01), the receptor postulated to be responsible for mediating the respiratory depression and gastrointestinal effects after morphine. This provides a possible explanation for the reduced respiratory depression and vomiting seen following morphine 6-glucuronide in man. A similar reduction in affinity of morphine 6-glucuronide was seen at the total mu receptor whilst there was no significant difference seen at the mu or delta receptor. Hence the increased analgesic potency of morphine 6-glucuronide over morphine remains unexplained.
Morphine is one of the commonest drugs prescribed by cancer physicians and is an effective potent analgesic. However one or more of the side effects of constipation, nausea and vomiting, and sedation are encountered frequently (Jaffe & Martin, 1991) . Respiratory depression is a less common problem but is the most potentially dangerous toxicity. An analgesic with equivalent potency but lower toxicity would therefore be of particular use.
The major metabolic products of morphine are morphine 3-glucuronide (M3G) and morphine 6-glucuronide (M6G). Although M3G is devoid of analgesic activity, M6G is now thought to play a major role in mediating the analgesic effect of morphine (Osborne et al., 1986; Hanks et al., 1987; Hanks, 1990) . When given directly M6G has been demonstrated to have more potent antinociceptive activity than morphine in animals (Shimomura et al., 1971; Pasternak et al., 1987; Abbott & Palmour, 1988; Paul et al., 1989) . It is tempting to presume the receptor binding profile of morphine and M6G is similar with M6G purely binding more avidly to the same receptors as morphine. However there are now several pieces of biochemical and clinical evidence to suggest this is not the case. Shimomum et al. (1971) found the systemic LD50 of M6G to be 88% that of morphine and hence first suggested the lethal effects of M6G did not directly correlate with its analgesic potency advantage over morphine. In addition glucuronidation is normally a natural mechanism of the body to detoxify noxious substances.
An open study in man (Osborne et al., 1989) provided anecdotal evidence in man that M6G may have a better toxicity profile than morphine as no nausea or sedation was seen at doses sufficient to give significant pain relief. A recent double-blind randomised study comparing the respiratory depression induced by equipotent doses of morphine and M6G in normal volunteers (Thompson et al., 1990) (Gilbert & Martin, 1976; Lord et al., 1977; Wuster et al., 1979; Wolozin et al., 1981; Pasternak et al., 1980 . Gouarderes et al., 1981 Rothman & Westfall, 1982) , but there remains controversy over the existence and the functional and structural relationships of the various opioid receptor subtypes, particularly of the mu and delta receptor. Despite this, recent developments in producing selective enkephalin agonists has enabled the comparative affinity of different compounds to individual types of receptor to be determined via radioligand binding studies.
For the purpose of the current study we have chosen the model proposed first by Pasternak and colleagues (Wolozin & Pasternak, 1981) . This model suggests there is a common receptor labelled by either a prototypic delta agonist such as DADLE (D-Ala2, D-Leu5-enkephalin) or with a mu agonist such as morphine which has high affinity for morphine. This they termed the mu 1 receptor. The receptor labelled with a mu agonist which possessed a lower affinity they termed the mu 2 receptor. Similarly the receptor labelled with a delta agonist possessing lower affinity for morphine they termed the true delta receptor.
It has been postulated that several of the adverse affects including respiratory depression of morphine are due to activation of the mu 2 or lower affinity mu opioid receptor (Pasternak & Wood, 1986 (Goldstein et al., 1971) Assay procedure The list of synthetic enkephalin ligands used with their assumed receptor specifities is displayed in Table I . All assays for specific binding were performed in triplicate in 10 ml plastic test tubes and assays for total binding and nonspecific binding performed in quadruplicate using the following experimental procedure:
Total bindings (i) 0.5 ml P2 (4 mg ml-').
(ii) 0.1 ml 3H-DSLET (1.5 nM) (mu 1 and delta assays) or 0.1 ml 3H-DAGO (1.5 nM) (total mu and mu 2 assays).
(iii) 0.1 ml Tris-HCl buffer (pH 7.4 at room temperature). Vortex and pre-incubate in shaking water bath at 37°C for 5 min.
(iv) 0.1 ml Tris-HCl buffer. Vortex and incubate in shaking water bath at 37°C for a further 15 min. Non-specific binding (i) 0.5ml P2 (4mgml-').
(ii) 0.1 ml 3H-DSLET (1.5 nM) (mu 1 and delta assays) or 0.1 ml 3H-DAGO (1.5 nM) (for total mu and mu 2 assays).
(iii) 0.1 ml DPDPE (20 nM) (mu 1 assay), 0.1 ml DSLET (5 nM) (mu 2 assay), 0.1 ml DAGO (5 nM) (delta assay) or 0.1 ml Tris-HCI buffer (total mu assay). Vortex and pre-incubate in shaking water bath at 37°C for 5 min.
(iv) 0.1 ml DSLET (1 ILM) (mu 1 assay), 0.1 ml DAGO (1I 1M) (total mu and mu 2 assays) or 0.1 ml DSLET (1 ltM) (delta assay).
Vortex and incubate in shaking water bath at 37'C for a further 15 min.
Specific binding (i) 0.5 ml P2 (4mg ml-').
(ii) 0.1 ml 3H-DAGO (1.5 nM) (total mu and mu 2 assays) or 0.1 ml 3H-DSLET (1.5 nM) (mu and delta assays).
(iii) 0.1 ml Tris-HCl buffer (total mu assay), 0.1 ml DPDPE (20 nM) (mu 1 assay), 0.1 ml DSLET (5 nM) (mu 2 assay) or 0.1 ml DAGO (5 nM) (delta assay). Vortex and pre-incubate in shaking water bath at 37°C for 5 min.
(iv) 0.1 ml DSLET (mu 1 and delta assays), DAGO (total mu and mu 2 assays), morphine or M6G standards at concentrations specified below, or 0.1 ml TrisHCl buffer. Vortex and incubate in shaking water bath at 37°C for 15min.
Following the second incubation the procedure for all assays was identical. The reaction was stopped by the addition of 5 ml ice cold Tris-HCl buffer to all tubes. The resulting solution was filtered through Whatman GF/B glass fibre filters using a Baker 10 extraction system capable of filtering ten samples simultaneously. The filter was washed twice with 5 ml of 10 mM Tris-HCl buffer and placed in scintillation bottles with 5 ml scintillant fluid (Ecoscint, National Diagnostics). Four unused filter papers were impregnated with 0. (1989) . As it is the mu 2 receptor which is thought to be responsible for principally mediating the lethal effects of morphine (Wolozin & Pasternak, 1981) , particularly respiratory depression (Ling et al., 1983; Ling et al., 1985) , this study provides a possible explanation for the significantly lower degree of respiratory depression, nausea and vomiting and sedation observed in man after M6G than after morphine (Thompson et al., 1990) . The difference in binding affinity also takes on more significance when considering the observation that M6G has approximately three times the systemic analgesic potency of morphine (Shimomura et al., 1971; Pasternak et al., 1987; Abbot & Palmour, 1988 , Thompson et al., 1990 . Despite this marked reduction in binding affinity for the mu 2 receptor M6G undoubtedly still causes respiratory depression when plasma concentrations are high (Hasselstrom et al., 1989; Osborne et al., 1986) . This is particularly observed in patients with renal failure administered morphine as the major excretion route of M6G is renal. The respiratory depression seen in this situation may be not only due to the high plasma concentrations of M6G binding to the mu2 receptor, but possibly also due to binding to the delta receptor which has also been suggested to play a role in mediating respiratory depression (Morin-Surun et al., 1984; Pazos & Florez, 1983; Pazos & Florez, 1984) . The 4-to 5-fold higher affinity of morphine for the mu 2 receptor was also seen over the total mu receptor population. This is not surprising as approximately 70% of mu receptors are mu 2 receptors (Chang & Cuatrecasas, 1979; Wolozin & Pasternak, 1981) (Wolozin & Pasternak, 1981; Pasternak et al., 1986 (Paul et al., 1989) . There are several reasons why this apparent inconsistency may exist. Firstly and most importantly, radiolabelled affinity studies only reflect the binding of a compound to a receptor, not activation of that receptor to produce a physiological response. Hence there may be differences in intrinsic activity of morphine and M6G at the receptor once bound. These differences may result in differing activation of the second messenger system, or differences in the allosteric modulation of nearby delta receptors possibly existing in an 'opioid receptor complex' in the opioid receptor model described by Rothman et al. (1982) . It is now realised the delta receptor plays a larger role in mediating supraspinal analgesia than was first thought although it is likely this role is mainly modulatory (Heyman et al., 1988; Heyman et al., 1989; Mathiasen et al., 1987) .
Secondly, the kappa receptor may also have a minor role in mediating supraspinal analgesia (Millan et al., 1989) and the affinity of M6G for the kappa receptor has not yet been accurately determined although is thought to be low (Pasternak et al., 1987) . Thirdly, binding studies are carried out in particular physiological conditions which can only approximate the situation in vivo. Further study of the interactions of M6G and morphine with opioid receptors at a molecular level is clearly required.
In conclusion, this study has demonstrated a significantly lower affinity of M6G in comparison to morphine for the mu 2 opioid receptor, the receptor postulated to be the principal mediator of the respiratory depression and gastrointestinal effects of morphine. It hence offers one possible explanation for the observation that M6G induces less respiratory depression and vomiting than equipotent doses of morphine in man. However, the marked analgesic potency of M6G over morphine remains unexplained and further study into the molecular interactions of M6G and opioid receptors and investigation of the second messenger system is clearly required. 
